

Notes of the Formulary Management Group

Held on	Tuesday 1 st October 2019			12:30pm (2:30pm finish) at Jubilee House, POD	
Members	Attended	Apologies	Absent	Designation	Abbreviation
	√			Head of Medicines Management	(C)
	√			Prescribing Adviser	(PA)
	√			Prescribing Adviser	(PA2)
	√			Trust Lead Formulary Pharmacist	(WHT FP)
	√			GP Lead for Medicines Management	(GP)
	√			Primary Care Pharmacist	(PCP)
			√	Clinical Nurse Specialist	(CNS)
			√	Nurse Non-Medical Prescriber	(NNMP)
	√			DWMHCP Chief Pharmacist	(DWMHCP)
		√		Patient Representative	(PR)
			√	LMC Representative	(LMC)
			√	Quality & Safety Officer	(QSO)
	√			Commissioning Administrator/Minute Taker	(CA)
	√			Consultant Cardiologist	(CC)
	√			Walsall Lead Community Pharmacist	(WLCP)
	√			Local Optical Committee Chair	(LOCC)

	Agenda item	Action
1.	<p><u>Welcome and Apologies (Declarations of AOB)</u></p> <p>C welcomed everyone to the meeting. Our PR did not attend the meeting.</p>	
2.	<p><u>Minutes of the Last Meeting</u></p> <p>It was advised of one small addition to the minutes for Emollients pathway- WHTFP had sent the email with the rationale of product inclusion used. Following this, the minutes were declared a true and accurate account of the meeting.</p>	
3.	<p><u>Matters Arising/Actions Sheet</u></p> <p>All actions have been updated on the Action Log, to be discussed during the meeting. The necessary actions have been completed and moved to the 'completed' tab, whilst actions from today's meeting are added accordingly.</p>	
4.	<p><u>Declarations of Interest (DOI) – Check Compliance</u></p> <ul style="list-style-type: none"> None 	
5.	<p><u>Non NICE TA Drug/devices - Full Applications</u></p> <p><u>Evolve Carmellose 0.5%</u> - LOCC presented to the committee. It was advised that this was a like for like switch. A search was completed and the Carmellose Evolve was the more cost effective option. C asked the committee if they would be happy to take forward to JMMC. LOCC discussed the price variations compared to other brands and doses. There were some discussions and queries around other products and their costs. WHTFP asked if a comparison to Cellusan had been completed.</p> <p>Action: LOCC to complete a comparison between Evolve Carmellose and Cellusan. Action: To be taken to JMMC, once details on the comparison has been completed.</p>	

Notes of the Formulary Management Group

	<p><u>Evolve HA 0.2%</u> – LOCC presented the application to the committee. This is a direct switch from hyloforte. There was a discussion about Evolve HA having a ‘blue tip’ technology, which is antibacterial.</p> <p>Action: LOCC to complete a comparison between Evolve HA and Clinitas. Action: To be taken to JMMC, once details on the comparison has been completed.</p>	
6.	<p><u>Trust Formulary Updates - Hospital only applications.</u> For information only.</p> <ul style="list-style-type: none"> • MMG Minutes June 19 • MMG Minutes July 19 • MMG Minutes September 19 <p>These were not discussed during the meeting.</p>	
7.	<p><u>NICE Technology Appraisal</u></p> <p>C advised WHTFP that a discussion needed to be had to ensure all relevant TAGs from NICE are added to the Joint Formulary. FP advised that all areas that state CCG on the NICE documentation, should then be added to the Formulary.</p> <p>Action: Ertugliflozin needs to be added to the Joint Formulary. Action: C and WHTFP to work together to add the medications to the Formulary.</p>	
8.	<p><u>Pathway/Guidelines</u></p> <p><u>Hypertension Pathway</u> – CC presented to the committee. These have been developed on an STP wide level. C has asked that if the committee are happy with these pathways, they can be taken to JMMC for ratification. CC advised that Walsall seem to be doing well with the pathway looking at the results presented.</p> <p>Action: CC to align numbers on the Hypertension Stage table (page 7) to support the NICE guidance. Action: CC to make an amendment to page 8 in relation to Hypertension. Action: CC to make amendments to ensure that LDL tabulates according to the risks involved. Action: CC to remove Aliskiren. Action: C to take to JMMC for ratification.</p> <p>12:45pm – DWMHCP entered the meeting.</p> <p><u>CVD Pathway</u> – CC presented the CVD pathway to the committee. Updated the committee on the various elements of the pathway, from the slideshow provided.</p> <p>Action: CC to add information to the page 18. Action: PA / CC to check read codes for the Hypertension, beta blockers (page 18). Action: C to take to JMMC for ratification. Action: C / PA to request this to be discussed at a PLT agenda in 2020.</p> <p>13:20pm – CC left the meeting.</p> <p><u>MECS Guidelines</u> – LOCC presented the Walsall Dry Eye Ophthalmic Formulary to the committee. Patients should still be encouraged to buy over the counter for short term use of the product.</p> <p>Action: Add the guidelines to JMMC for discussion once application queries above are resolved.</p>	

Notes of the Formulary Management Group

	<p>LOCC presented the Walsall Formulary Allergic Conjunctivitis to the committee. This is a revised version of the documentation. LOCC advised the committee of the eye medication that is on the Formulary application. Again, self-care is advised to be encouraged in the first instance.</p> <p>Action: LOCC to emphasise on restrictions of prescribing fusidic acid</p> <p>Action: To be taken to JMMC for ratification.</p> <p>Action: LOCC to look into other manufacturers costs and bring this back to C for information.</p> <p>14:00pm LOCC left the meeting.</p> <p><u>RMOC Liothyronine</u> – C advised of the slight amendments that have been made by PA2 in the ESCA guidance (highlighted in red on the papers). The ESCA has already been approved by FMG. C asked whether the committee were happy for this to be taken through to JMMC to be ratified.</p> <p>Action: To be taken to JMMC for ratification.</p>	
9.	<p><u>Drug Safety Update</u></p> <p>This was not discussed during the meeting.</p>	
10.	<p><u>Regional Medicines Optimisation Committee</u></p> <p>This was not discussed during the meeting.</p>	
11.	<p><u>Horizon Scanning</u></p> <p>This was not discussed during the meeting.</p>	
12.	<p><u>Appeals</u></p> <ul style="list-style-type: none"> • None 	
13.	<p><u>Formulary Breach</u></p> <ul style="list-style-type: none"> • Victoza • OPMRL • Afex urinal system • Lurasidone <p>FP advised that he had emailed out the necessary information on the breaches. DWMHCP advised the breach for Lurasidone has been completed.</p>	
14.	<p><u>Recommendations to JMMC</u></p> <ul style="list-style-type: none"> • None 	
15.	<p><u>Any other business</u></p> <p>This was not discussed at the meeting, to be taken forward to November FMG.</p>	
16.	<p style="text-align: center;">These minutes are a true representation of the Group’s proceeding</p> <p>Signed: _____ Chair _____ Date _____</p>	

These minutes will be redacted to remove names/initials before publication

Future Meeting Dates

Notes of the Formulary Management Group

2019								
Formulary Management Group Future Meeting Schedule 12:30pm Start (Finish 2:30pm)								
Date	Month	Year	Venue		Date	Month	Year	Venue
8 th	January	2019	Board Room		2 nd	July	2019	Board Room
5 th	February	2019	Room 3		6 th	August	2019	Board Room
5 th	March	2019	POD		3 rd	September	2019	Board Room
2 nd	April	2019	Board Room		1 st	October	2019	Board Room
7 th	May	2019	Board Room		5 th	November	2019	Board Room
4 th	June	2019	Board Room		3 rd	December	2019	Board Room